Oxford Gene Technology Appoints Dr David Owen to the Board
News Oct 05, 2005
Oxford Gene Technology (OGT) has announced the appointment of Dr David Owen to the OGT Board as a Non-Executive Director.
He went on to lead technology driven licensing agreements for SmithKline and French as Group Director for Compound and Technology Acquisitions.
In 1990 he joined the MRC as CEO of MRC Technology, and led technology transfer activities in patenting, licensing technologies, creating new "start-up" companies and generation of revenues.
In June 2001 David was awarded the OBE for services to medical research and technology transfer.
David is currently Non-Executive Chairman of Abcellute Ltd. and the Cardiff Partnership Fund, Co-Chairman of EMBL Enterprise Management, GmbH, in Heidelberg and is a past President of the Association of European Science and Technology Transfer Professionals.
David said, “I am delighted and very flattered to be invited to participate in the business of OGT.”
“The Company's leading technologies are fundamental tools in many facets of molecular biology research and thereby facilitate key advances in bioscience knowledge and understanding.”
“I look forward to joining fellow Directors in building on the current success of OGT and to help develop the Company further.”
Professor Sir Ed Southern, OGT's Chairman, said, “I am pleased to welcome David to the OGT Board.”
“He has had a distinguished career in pharmaceutical research and technology transfer and will bring a wealth of experience.”
Restoring the ability to walk following spinal cord injury requires neurons in the brain to reestablish communication pathways with neurons in the spinal cord, Mature neurons, however, are unable to regenerate their axons to facilitate this process. New research in mice shows one potential route to overcome this limitation may be by targeting liver kinase B1 (LKB1) protein.
International Conference on Cell and Structural biology
Jul 15 - Jul 16, 2019